SAN DIEGO, March 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the American Academy of Pain Medicine (AAPM) has presented Marsha R. Stanton, Ph.D., RN, Executive Director of Medical Affairs at Zogenix, with the Distinguished Service Award, recognition given annually to honor an individual for their outstanding commitment and contributions to the field of pain medicine and the AAPM.
Dr. Stanton is nationally known for her extensive work in pain management including clinical practice, public policy and patient education. Dr. Stanton has been an integral member of the AAPM Foundation, which focuses its efforts on advocating for patient safety by providing funding support to expand and enhance education and research, as well as encouraging improved training and credentialing as a way to advance pain management. As Treasurer, Board Member and Campaign Committee member for the Foundation, she has provided valuable leadership and contributions to the fundraising efforts of the Academy to pursue educational research initiatives.
"I've known Marsha for years through working with her on the corporate council of the American Academy of Pain Medicine, in addition to her work with the Academy's Foundation," said Martin Grabois, M.D., Professor, Department of Physical Medicine & Rehab at Baylor College of Medicine and AAPM Awards Committee Chair and Immediate Past President. "She has always been a shining light in helping the Academy pursue its goal to optimize the health of patients in pain and eliminate the major health problem of pain by advancing the practice and the specialty of pain medicine.""We congratulate Dr. Stanton on receiving this prestigious award and are proud to have her as part of our Medical Affairs team," said Bradley S. Galer, M.D., Executive Vice President and Chief Medical Officer of Zogenix. "She offers a wealth of experience and insight into pain medicine and we look forward to her leadership and guidance as we continue to deliver on our mission of developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions."